Benzinga | Aug 11, 2021 06:24AM EDT

Morgan Stanley Upgrades Fulcrum Therapeutics to Overweight, Announces $34 Price Target

Morgan Stanley analyst Matthew Harrison upgrades Fulcrum Therapeutics (NASDAQ:FULC) from Equal-Weight to Overweight and announces $34 price target.